louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05105191: Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room
Official title: Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Influenza Viral Infections
RSV Infection
Lead sponsor: Erasme University Hospital
Sponsor class: OTHER
Collaborators: name: LHUB-ULB
name: Roche Diagnostics GmbH
First posted: 2021-11-03
Enrollment: 280
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Molecular techniques for respiratory virus detection have already shown benefits in terms of sensitivity gained in comparison to conventional techniques. Recent progress has made it possible to shorten turnaround time (TAT) and to allow delivery of results in a timely manner, especially in comparison to cell culture and direct fluorescence assays (DFA). However, the cost of these molecular assays is usually not taken in charge by public health insurance system. This could be partly explained by the fact that molecular techniques have not clearly shown cost-effectiveness. Results of molecular tests for influenza viruses and RSV, if delivered rapidly, in the emergency room (ER), would most likely help avoid antibiotic use and ancillary test prescription, improve antiviral prescription and shorten length of stay in the ward by facilitating discharge or cohorting of hospitalized patients. The goal of this study is to assess the performances of Roche Cobas® Liat Influenza A/B \& RSV assay, to appraise its clinical impact and to evaluate its cost effectiveness.


Eligibility criteria: Inclusion Criteria:

* Either a pre-test indication of hospitalization
* or an underlying situation at risk of respiratory complication following influenza infection

Primary outcomes:
measure: Analytical performance (Sensitivity/Specificity)
timeFrame: through study completion, 6 months
measure: Hospital admission intentions
timeFrame: through study completion, 6 months
measure: Isolation intentions
timeFrame: through study completion, 6 months
measure: Antibiotic prescription intentions
timeFrame: through study completion, 6 months
measure: Antiviral treatment prescription intentions
timeFrame: through study completion, 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Brugmann Hospital
city: Brussels
country: Belgium
facility: Erasme Hospital
city: Brussels
country: Belgium
facility: HUDERF
city: Brussels
country: Belgium
facility: Saint-Pierre Hospital
Study officials:
References:
Clinical trial NCT00456391: The Utility of Performing Brain CT Scan in Non Trauma Patients at the Pediatric Emergency Unit
Official title: The Utility of Performing Brain CT Scan in Non Trauma Patients at the Pediatric Emergency Unit. A Retrospective Observational Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Convulsions
Increased Intracraneal Pressure
Keywords: Brain CT scan
Pediatric emergency room
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2007-04-05
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Pediatric patients are admitted to the emergency room for diverse causes, beside trauma, patients can present with convulsions, suspicion of brain tumor or increased intracranial pressure. In most of the cases a brain CT is performed even before physical examination by a skilled neurologist. The amount of radiation that the children are exposed is equivalent to 100 plain chest X rays. The purpose of this tudy is to examinate in a retrospective study what were the indications for CT study and what was the incidence of relevant abnormal findings that required emergency intervention or referral.


Eligibility criteria: Inclusion Criteria:

* All patients in the pediatric age that underwent brain CT scan in the pediatric emergency room

Exclusion Criteria:

* Patients with recent history of trauma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Pediatric Dpt B and Pediatric Emergency Room - HaEmek Medical Center
Study officials:
affiliation: Pediatric Hematology Unit, Ha'Emek Medical Center
name: Ariel Koren, MD
role: STUDY_DIRECTOR
affiliation: Pediatric Dpt B - Ha'Emek Medical Center
name: Waheeb Sakran, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Pediatric Dpt B - Ha'Emek Medical Center
name: Izat Hatib, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02978391: UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD
Official title: A Prospective, Multicenter, Single-blind, Controlled Clinical Trial to Confirm the Efficacy and Safety of 'UI-EWD', a Wound Dressing Used for Wound Protection and Hemostasis After Ulcer Bleeding Due to Peptic Ulcer, EMR and ESD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Upper Gastrointestinal Bleeding
Lead sponsor: Next Biomedical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-11-30
Enrollment: 76
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: UI-EWD (NextBiomedical Co, Incheon, South Korea), a new hemostatic powder for endoscopic treatment of high-risk bleeding peptic ulcers and bleeding after ESD/EMR.

Detailed description: UI-EWD (Endoscopic Wound Dressing) is adhesive absorbable powder as a new hemostasis material, the therapeutic effect and safety in endoscopic application will be verified. This study has been designed to observe comparing UI-EWD versus the submucosal epinephrine injection for endoscopic hemostasis of bleeding peptic ulcers and bleeding after EMR/ESD.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of bleeding peptic ulcer and active bleeding after ESD/EMR

Exclusion Criteria:

* Coagulation disorder (PLT \< 50\*10\^9/L, INR \> 2)
* Connot stop taking the antiplatelet drug, NSAID, Anticoagulant drug, and Aspirin during endoscopic treatment and after 72h endoscopy

Primary outcomes:
measure: Recurrent bleeding rate
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Bucheon
country: Korea, Republic of
facility: Soonchunhyang University College of Medicine
city: Incheon
country: Korea, Republic of
facility: Inha University Hospital
Study officials:
affiliation: Inha University Hospital
name: Yong-Woon Shin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00722891: Ocular Responses to Short and Long-term Lens Wear
Official title: Ocular Responses to Acute and Chronic Lens Wear
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ametropia
Keywords: Eye Diseases
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
First posted: 2008-07-28
Enrollment: 30
Sex: ALL
Minimum age (years): 17
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study was to determine whether ocular surface sensitivity to pneumatic, mechanical and chemical stimulation would be affected by the use of the combination of a specific silicone hydrogel lens material with two lens care products over a four week period.


Eligibility criteria: Inclusion Criteria:

* Is at least 17 years old and has full legal capacity to volunteer;
* Is correctable to a visual acuity of 6/7.5 (20/25) or better (both eyes) with their habitual vision correction;
* Is a current soft lens wearer and wears contact lenses six or more days/week;
* Has clear corneas and no active ocular disease.

Exclusion Criteria:

* Has any clinically significant blepharitis or dry eye;
* Has undergone corneal refractive surgery;
* Is aphakic;
* Has any active ocular disease;
* Has any systemic disease affecting ocular health;
* Is using any systemic or topical medications that may affect ocular health;

Primary outcomes:
measure: Quantify the ocular response to acute and chronic lens wear using slit lamp examination, tear assay and corneal sensitivity.
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Waterloo
country: Canada
facility: University of Waterloo
state: Ontario
Study officials:
affiliation: University of Waterloo
name: Trefford Simpson, DipOptom,MSc,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01294891: Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
Official title: Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheologic Disease
Sickle Cell Disease
Paroxysmal Nocturnal Hemoglobinuria
Keywords: Rheology
Sickle cell
Paroxysmal nocturnal hemoglobinuria
contrast ultrasound
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2011-02-14
Enrollment: 6
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with SCD or PNH who are seen in the OHSU Hematology clinic and are asked to participate

Brief summary: The purpose of this study is to examine how abnormal blood flow in the small vessels (microvessels) of the heart, muscle and kidney in paroxysmal nocturnal hemoglobinuria (PNH) or sickle cell disease leads to poor functioning of the heart and kidney. To test this question, the investigators will perform imaging tests (contrast ultrasound perfusion imaging) to look at the flow and function of these microvessels and compare this information to heart and kidney function. To further look at this question, patients who have PNH will be studied before and after starting a new drug (Soliris) that decreases damage to blood cells. In patients with sickle cell disease, patients will be studied at baseline (not during a pain crisis) and also during a pain crisis if one develops.


Eligibility criteria: Inclusion Criteria:

* Established diagnosis of PNH or SCD Age \> 18 years old

Exclusion Criteria:

* Pregnant or lactating women Presence of significant right to left shunting Allergy to ultrasound contrast agent Reactive airways disease Significant peripheral or coronary artery disease

Primary outcomes:
measure: Microvascular perfusion
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
References:
Clinical trial NCT01865591: Feasibility Study of Renal Denervation for the Treatment of Resistant Hypertension
Official title: A Clinical Trial for the Assessment of Safety and Efficacy of the UltraSOUND Mediated InTerVentional Treatment of Resistant Hypertension
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Uncontrolled Hypertension
Keywords: hypertension
uncontrolled hypertension
resistant hypertension
Lead sponsor: Sound Interventions, Inc.
Sponsor class: INDUSTRY
First posted: 2013-05-31
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to assess the potential therapeutic benefit of catheter-based renal sympathetic denervation using therapeutic unfocussed ultrasound in a single-arm feasibility trial.


Eligibility criteria: Inclusion Criteria:

* Uncontrolled hypertension (defined as SBP ≥ 140 mmHg during 24Hr Ambulatory BP monitoring)
* Current treatment with ≥ 3 anti-hypertensive drugs (including at least one diuretic)
* Renal artery diameter ≥5mm by digital angiography
* Accessibility of renal vasculature

Exclusion Criteria:

* Estimated GFR \< 45
* Type 1 Diabetes
* Known renovascular abnormalities (eg, renal artery stenosis, previous renal artery stenting or angioplasty)

Primary outcomes:
measure: Major adverse events
timeFrame: 30 days
Secondary outcomes:
measure: Change from baseline in office blood pressure measurement
timeFrame: 30 days, 3 months, 6 months, 9 months, 12 months
measure: Change from baseline in ambulatory 24-hour blood pressure measurement
timeFrame: 6 months, 12 months
measure: Change from baseline in renal artery dimensions
timeFrame: 30 days
measure: Change from baseline in creatinine
timeFrame: 6 months
measure: Adverse events and device complications
timeFrame: 12 months
Other outcomes:
Locations:
city: Prague
country: Czech Republic
facility: Na Homolce Hospital
Study officials:
References:
Clinical trial NCT00219791: Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
Official title: Study of Recombinant Carboxypeptidase G2 (CPG2) for the Management of Patients With Delayed Methotrexate (MTX) Clearance or Intrathecal MTX Overdosage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neoplasms
Keywords: methotrexate
delayed elimination
renal insufficiency
CPG2
Voraxaze
Lead sponsor: BTG International Inc.
Sponsor class: OTHER
First posted: 2005-09-22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate (MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with intrathecal MTX overdose.


Eligibility criteria: Inclusion Criteria:

* Written informed consent by patient or legally valid representative
* Patients receiving high-dose MTX (\>1 g/m2 body surface area (BSA) given as an infusion over 24 hours) for the treatment of ALL, NHL or a solid tumour (e.g. osteosarcoma)
* Age ≥ 18 years
* Serum MTX \>5 µmol/L 42 hours or later after the start of MTX infusion, or serum MTX \>1 μmol/L 42 hours or later after the start of MTX infusion together with renal insufficiency, or serum MTX \>0.4 µmol/L 48 hours or later after the start of MTX infusion together with renal insufficiency. Renal insufficiency was defined as serum creatinine \>1.5 × the upper limit of normal (ULN) and/or oliguria (urine output \< 500 mL/24 hours despite adequate hydration, diuretics and alkalinisation).

Exclusion Criteria:

* Pregnant or lactating females
* Unwillingness of patient or relative/legal representative to give informed consent

Primary outcomes:
measure: Reduction in serum MTX concentration
Secondary outcomes:
measure: serum blood-urea-nitrogen
measure: serum creatinine
measure: creatinine clearance
measure: haematology (complete blood count and differential)
measure: biochemistry (electrolytes, SGOT, SGPT, alkaline phosphatase, bilirubin, total protein)
measure: urinalysis (dip-stick)
measure: MTX-related toxicity
measure: Adverse events
measure: Mortality
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charite - Universitätsmedizin Berlin
Study officials:
affiliation: Charite - Universitätsmedizin Berlin
name: Thiel Eckhard, Prof. Dr.med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02375191: A Comparative Study of the Effect of Epidural Dexmedetomidine Versus Fentanyl Added to Ropivacaine in Pediatric Orthopedic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Congenital Skelectal Anomaly
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2015-03-02
Enrollment: 58
Sex: ALL
Minimum age (years): 3
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of epidural dexmedetomidine added to ropivacaine in pediatric orthopedic surgery


Eligibility criteria: Inclusion Criteria:

* pediatric patients aged from 3 to 12 years undergoing orthopedic mechanical correction surgery

Exclusion Criteria:

* coagulopathy, refusal (parents), current infection on the lumbar area, spinal tract pathology

Primary outcomes:
measure: Postoperative pain score
timeFrame: During 48 hrs after pediatric orthopedic surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Study officials:
References:
Clinical trial NCT05833191: Efficacy of Different Nerve Stimulation Methods in Individuals With Chronic Constipation
Official title: Efficacy of Different Nerve Stimulation Methods in Individuals With Chronic Constipation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Constipation
Keywords: vagus
tibial nerve stimülation
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-04-27
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study will be included in a 12-session treatment program over four weeks.
Primary purpose: TREATMENT

Brief summary: Constipation is the most common digestive complaint in the general population. Normal stool frequency ranges from at least three times a week to a maximum of two times a day. Constipation can be classified into three main groups as constipation with normal transit time, constipation with slow transit time and dyssynergic defecation disorders.

Detailed description: In chronic constipation, treatment should be directed towards the underlying cause. In the treatment of chronic constipation, lifestyle changes and physiotherapy are in the first place, pharmacological treatment is in the second place, and surgical treatment is in the third place. Physiotherapy modalities such as defecation training, classical massage, electrical stimulation, anorectal biofeedback and exercise training can be used in the treatment of chronic constipation.

Eligibility criteria: Inclusion criteria:

•Being diagnosed with chronic constipation

Exclusion criteria:

* Metabolic diseases
* Severe heart or kidney disease, previous gastrointestinal, spinal or pelvic surgery other than cholecystectomy, hysterectomy or appendectomy,
* Neurological diseases such as multiple sclerosis, stroke, Parkinson's disease or spinal injury, impaired awareness
* Mini-mental score \< 15
* Legal blindness, pregnancy, rectal prolapse, anal fissure, and alternating pattern of constipation and diarrhea.

Primary outcomes:
measure: Bristol Stool Scale
timeFrame: 4 weeks
measure: Pelvic Pain Impact Questionnaire
timeFrame: 4 weeks
measure: Superficial Electromyography Biofeedback
timeFrame: 4 weeks
measure: Constipation Severity Scale
timeFrame: 4 weeks
measure: Autonomic nervous system device
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Medipol hospital
state: Istanbul Avrupa Kitasi
city: Istanbul
country: Turkey
facility: Medipol hospital
Study officials:
References:
citation: Tan K, Wells CI, Dinning P, Bissett IP, O'Grady G. Placebo Response Rates in Electrical Nerve Stimulation Trials for Fecal Incontinence and Constipation: A Systematic Review and Meta-Analysis. Neuromodulation. 2020 Dec;23(8):1108-1116. doi: 10.1111/ner.13092. Epub 2019 Dec 30.
Clinical trial NCT00894491: Complementary and Alternative Medical Trends: A Patient Survey in a University Based Clinic
Official title: Complementary and Alternative Medical Therapy Trends: A Patient Survey in a University Based Clinic
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Complementary and Alternative Therapies
Keywords: alternative medicine
complementary medicine
acupuncture
Chinese herbals
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2009-05-07
Enrollment: 0
Sex: ALL
Minimum age (years): 41
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 14 male, 19 female white non-Hispanic, college educated over the age of 41

Brief summary: Patient survey identifying key elements of patient experience and decision-making processes regarding attendance University of California, Irvine (UCI)'s Integrative Medicine Clinic.

Detailed description: Patient survey to determine why patients come to UCI's integrative medicine clinic, whether they would prefer we accept insurance coverage, and what therapies they are using.

Eligibility criteria: Inclusion Criteria:

* Adult patients 41 years of age or older
* English speaking
* Ability to provide informed consent
* Patient at Gottschalk Medical Plaza Integrative Medical Clinic
* Ability to complete survey

Exclusion Criteria:

* Patient less than 41 years of age
* Inability to speak English
* Patient unable to provide informed consent
* Patient not being seen at Gottschalk medical Plaza Integrative Medical Clinic
* Incomplete survey

Primary outcomes:
measure: Why People Chose Complementary and Alternative Therapies
timeFrame: Post-care
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
facility: UCI Samueli Center Clinic
state: California
Study officials:
affiliation: UC Irvine School of Medicine
name: John Longhurst, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: